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Introduction
Smudge cells, also known as Gumprecht cells1 are ragged
lymphoid cells found mainly in peripheral blood smears of
patients with chronic lymphocytic leukemia (CLL) and other
B-cell chronic lymphoproliferative diseases (CLD). Smudge
cells are not simply artifacts of slide preparations and there is
Smudge cells in peripheral blood smears did not differentiate chronic lymphocytic
leukemia from other B-cell chronic lymphoprolipherative diseases
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 Smudge cells has been classically associated with chronic lymphocytic leukemia (CLL),
but they are found in peripheral blood tests for other chronic B-cell lymphoproliferative
diseases (CLD). We investigated whether the percentage of smudge cells in peripheral
blood smears can be used in the clinical practice to differentiate CLL from other B-cell
CLD. The peripheral blood smears of 63 patients with the diagnosis of CLL and 62 with
other B-cell CLD were analyzed. Three hundred cells (both lymphoid cells and smudge
cells) were counted for each peripheral blood smear. A comparison of the percentage of
smudge cells between the two groups was performed and, subsequently, 5 cut-off values
were fixed (10%, 20%, 30%, 40% and 50% of smudge cells) with the aim of defining
cases as "positive" or "negative" for smudge cells and verifying whether there are any
differences between CLL and the other B-cell CLD. The percentage of smudge cells in
patients with CLL (median 26%, 4%-86%) was higher than in patients with B-cell CLD
(median 14%, 1%-64%). However, none of the cut-off values tested presented suitable
values of sensitivity, specificity and positive predictive value to separate the two groups.
As it is necessary to have a single cut-off value with high sensitivity, specificity and
positive predictive value to infer the diagnosis of CLL in the clinical practice, we
concluded that smudge cells are not fitting to differentiate CLL from other B-cell CLD.
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no correlation between absolute lymphocyte count and the
percentage of these cells.2
Therefore they may be related to the biological
characteristics of leukemic cells, as demonstrated in a recent
paper where low vimentin expression could render CLL cells
more susceptible to smudging when making peripheral blood
smears.3
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Although smudge cells can be found in different B-cell
CLD and even in reactive lymphocytosis,4 they have been
classically associated with the diagnosis of chronic
lymphocytic leukemia. In fact, even in recent publications
the smudge cells are considered a typical finding which
strongly suggests the diagnosis of chronic lymphocytic
leukemia.5
In this study, we investigated if the percentage of
smudge cells in peripheral blood smears could really be used
in the clinical practice of hematology to differentiate CLL
from other B-cell CLD.
Design and Method
Patients
We analyzed the peripheral blood smears of 125
patients with the diagnosis of mature B-cell neoplasm: 63
with chronic lymphocytic leukemia and 62 with other B-cell
chronic lymphoproliferative disorders (31 with mantle-cell
lymphoma, 11 with splenic marginal B-cell lymphoma, 5 with
B-cell prolymphocytic leukemia, 5 with follicular lymphoma,
3 with lymhoplasmacytic lymphoma, 1 with hairy cell
leukemia and 6 patients with a B-cell lymphoproliferative
disorders not otherwise categorized). All cases of CLL had
4 or 5 points in the Matutes scoring system,6 while all other
CLD cases had 0, 1 or 2 points. We excluded all patients
with 3 points in the scoring system. The patients' diagnosis
was based mainly on morphological and immuno-
phenotypical features. All mantle-cell lymphoma cases had
evidence of CYCLIN D1 overexpression measured by real-
time polymerase chain reaction (data not shown). All
peripheral blood slides belong to the "Blood and Bone
Marrow Bank" of the Laboratory of Hematology, University
of Sao Paulo, which was approved by the Ethics Commitee
of University Hospital, School of Medicine of  Ribeirao
Preto.
Morphological examination and
immunophenotyping
The blood smears of all samples were prepared from
either EDTA anticoagulated blood or a finger stick, by manual
wedge method, in which a drop of blood is pulled by a glass
cover. Three-hundred cells, among lymphoid cells and
smudge cells, were counted simultaneously by two
hematologists on each peripheral blood smear stained with
Leishman stain, and 10% of the samples were randomly
selected to be blindly reviewed by a third independent
investigator. All samples were considered to be consistent
with the diagnosis of a mature B-cell neoplasm on morphologic
examination.
Mononuclear cells were isolated from peripheral blood
samples by Fycoll Hypaque density gradient centrifugation.
The following panel of monoclonal antibodies directly
conjugated with fluorescein isothiocyanate (FITC) or
phycoerythrin (PE) was used: CD2, CD5, CD10, CD19, CD23,
CD79b, CD103, FMC7, Kappa/Lambda-immunoglobulin light
chain. All monoclonal antibodies were purchased from Becton
Dickinson, except FMC7 (Dako, USA). All samples were
analyzed with a FACScan (Becton Dickinson, San Jose, CA).
The Cell Quest software was used for data acquisition and
analysis.
Statistics
The samples did not present a normal distribution
based on the Kolmogorov-Smirnov test performed with the
SPSS 9.0 software. So, the comparison of the percentage of
smudge cells between the two groups (CLL vs. B-cell CLD)
was performed by the Mann-Whitney test, two-tailed, using
GraphPad 4.0 Prism software. Subsequently, we fixed 5 cut-
off values of more than 10%, 20%, 30%, 40% and 50% of
smudge cells with the purpose to define a case as "positive
for smudge cells" and verify if there were any differences
between CLL and the others CLD. We used a Fisher's exact
Figure 1. Median (horizontal bars) of percentage of smudge cells between chronic lymphocytic leukemia (CLL) and other B-cell chronic
lymphoproliferative diseases (CLD)
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test, and a p value of less than 0.05 was considered of
statistical significance.
Results
The percentage of smudge cells in peripheral blood
smears of patients with the diagnosis of chronic
lymphocytic leukemia [26% (range, 4%-86%)] was higher
than in patients with B-cell chronic lymphoproliferative
disorders [14% (range, 1%-64%)] (p=0.0005) (Figure 1). We
then analyzed the discriminating capacity of the five different
cut-offs. Table 1 show that percentages of smudge cells
equal or higher than 10%, 20% and 30% were found to
generate two subgroups with frequencies of CLL cases
statistically different. We determined the variables related
to the tests (sensitivity and specificity) and the positives
predictives values in order to verify if the separation between
the CLL and the others CLD could really be possible on
clinical grounds (Table 2).
differentiation between CLL and CLD. We calculated the
sensitivity and the specificity of 10%, 20% and 30% cut-
offs, since these pre-test variables are the most important
determinants of the utility of any diagnostic test intended
to be used in clinical practice. Moreover, we calculated the
positive predictive value because this post-test probability
is, in fact, the value used by clinicians in their diagnosis
decision process (Table 2).
The cut-off of 10% has presented the higher
sensitivity (89%), and the cut-off of 30% has presented the
higher specificity (81%) for the diagnosis of CLL. However,
the cut-off of 10% has showed a low specificity (27%), and
the cut-off of 30% has showed a low sensitivity (36%). The
cut-off of 20% has presented intermediate values of
sensitivity and specificity (65% and 63%, respectively).
Thus, for each one of the three "tests", the probability of
be positive (percentages of smudge cells higher than the
cut-off) provided that the diagnosis is CLL, and, at the same
time, the probability of be negative (percentages of smudge
cells lower than the cut-off) provided that the
diagnosis is not CLL are not sufficient to
precisely separate between the CLL and the
others CLD. This occurs because there is an
overlay of smudge cells' percentages in both
CLL and CLD. Besides, the probability that a
patient has the diagnosis of CLL provided
that the test is positive (positive predictive
value) based on that three cut-offs is low and
also not sufficient to distinguish the two
groups.
Hence, even if the percentage of smudge cells in CLL
was higher than in patients with CLD when we compared
directly the two groups, it would be necessary to have a
single cut-off value with higher sensitivity, specificity and
positive predictive value to infer the diagnosis of CLL in
clinical practice.
When using a test as a diagnostic tool, the validity of
the test, measures by the rates of sensitivity and specificity,
is what gives the information about the value of the test for
its clinical application. Smudge cells on peripheral blood
smears are, at most, "statistically significant", but, essentially,
they are not "clinically significant" to discriminate CLL from
other CLD.
In clinical medicine, it is very common that a reasonable
and general assumption among physicians become
Discussion
The presence of smudge cells has been classically
associated with the diagnosis of chronic lymphocytic
leukemia. In this study, we investigated the presence of
smudge cells in 125 randomly selected patients with mature
B-cell neoplasms, with the purpose to verify if the widespread
belief that smudge cells are more frequently associated with
the diagnosis of chronic lymphocytic leukemia is a true
conception.
Thus, three cut-offs were found to be able, in theory,
to separate CLL patients from CLD patients: 10%, 20% and
30%. Since these values have allowed a statistically valid
separation between the two groups, we have considered
which one of them as a "test" to be used in the
considered a really proved medical information. These
"widespread beliefs" occur mainly because they make some
pathophysiologic sense, but they are infrequently submitted
to clinical studies.7 The results of this report show clearly
that, on clinical grounds, the percentage of smudge cells in
peripheral blood smears have no value as a morphologic
finding for the differentiation between CLL and others B-cell
CLD.
Resumo
As sombras nucleares têm sido classicamente associadas à
leucemia linfocítica crônica (LLC), embora possam ser encon-
tradas nos esfregaços do sangue periférico de outras doenças
linfoproliferativas B crônicas (DLBC). Nesse estudo, nós investi-
gamos se a porcentagem de sombras nucleares nos esfregaços do
sangue periférico pode ser utilizada na prática clínica da hemato-
logia para diferenciar a LLC das outras DLBC. Foram analisados
os esfregaços do sangue periférico de 63 pacientes com o diag-
nóstico de LLC e 62 com outras DLPC. Trezentas células, entre
células linfoides e sombras nucleares, foram contadas em cada
esfregaço. A comparação da porcentagem de sombras nucleares
entre os dois grupos foi realizada e, subsequentemente, foram
fixados 5 cut-offs de mais de 10%, 20%, 30%, 40% e 50% de
sombras nucleares com o propósito de definir um caso como
"positivo para sombras nucleares" e verificar se havia diferenças
entre a LLC e as outras DLBC. A porcentagem das sombras
nucleares em pacientes com LLC (mediana 26%, 4%-86%) foi
maior do que em pacientes com DLBC (mediana 14%, 1%-64%).
Entretanto, nenhum dos cut-offs testados apresentou valores
apropriados de sensibilidade, especificidade e valor preditivo
positivo para distinguir os dois grupos. Desde que é necessário
se dispor de um único valor de cut-off com alta sensibilidade,
especificidade e valor preditivo positivo para inferir o diagnóstico
de CLL na prática clínica, conclui-se que as sombras nucleares
não são úteis para diferenciar a LLC das outras DLBC. Rev.
Bras. Hematol. Hemoter.
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